Marianna Buttarelli1, Floriana Mascilini2, Gian Franco Zannoni3, Alessandra Ciucci1, Enrica Martinelli1, Flavia Filippetti1, Giovanni Scambia2, Gabriella Ferrandina4, Daniela Gallo5. 1. Unit of Translational Medicine for Women and Children Health, Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy. 2. Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy. 3. Department of Pathology, Catholic University of the Sacred Heart, Rome, Italy. 4. Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy; Department of Health Sciences and Medicine, University of Molise, Campobasso, Italy. 5. Unit of Translational Medicine for Women and Children Health, Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy. Electronic address: daniela.gallo@unicatt.it.
Abstract
OBJECTIVE: Low-grade serous ovarian carcinomas (LGSOCs) are a histological subtype of epithelial ovarian tumors, accounting for fewer than 5% of all cases of ovarian carcinoma. Due to the chemoresistant nature of this subtype a search for more effective systemic therapies is actively ongoing, hormonal therapy showing some degree of activity in this clinical setting. The present study ought to investigate the hormone receptor status of LGSOCs, as a strategy to provide molecular support for patient-tailored hormonal treatments. METHODS: Estrogen receptor α (ERα), ERβ isoforms (i.e. ERβ1, ERβ2 and ERβ5), progesterone and androgen receptor (PR, AR) expression was evaluated by immunohistochemistry in 25 untreated LGSOC primary tumors, 6 matched metastases and 6 micropapillary variant of serous borderline tumors (micropapillary SBOTs). In vitro cellular models were used to provide insights into clinical observations. RESULTS: Our results showed prominent expression of nuclear ERα, ERβ2, ERβ5 and PR in LGSOC primary tissues, while metastatic lesions also exhibit considerable cytoplasmic ERβ2 levels. Notably, a higher expression of ERβ1 protein was determined in micropapillary SBOTs compared to LGSOCs. In vitro experiments on LGSOC cell lines (i.e. HOC-7 and VOA-1056) revealed low/absent ERα, PR and AR protein expression, whereas the three ERβ isoforms were all present. Proliferation of HOC-7 and VOA-1056 was not modulated by either the endogenous or the selective synthetic ligands. CONCLUSIONS: These novel findings highlight the need of assessing relative levels of ERα and ERβ isoforms in the total receptor pool in future clinical studies investigating molecular predictors of response to hormonal therapy in LGSOC.
OBJECTIVE: Low-grade serous ovarian carcinomas (LGSOCs) are a histological subtype of epithelial ovarian tumors, accounting for fewer than 5% of all cases of ovarian carcinoma. Due to the chemoresistant nature of this subtype a search for more effective systemic therapies is actively ongoing, hormonal therapy showing some degree of activity in this clinical setting. The present study ought to investigate the hormone receptor status of LGSOCs, as a strategy to provide molecular support for patient-tailored hormonal treatments. METHODS: Estrogen receptor α (ERα), ERβ isoforms (i.e. ERβ1, ERβ2 and ERβ5), progesterone and androgen receptor (PR, AR) expression was evaluated by immunohistochemistry in 25 untreated LGSOC primary tumors, 6 matched metastases and 6 micropapillary variant of serous borderline tumors (micropapillary SBOTs). In vitro cellular models were used to provide insights into clinical observations. RESULTS: Our results showed prominent expression of nuclear ERα, ERβ2, ERβ5 and PR in LGSOC primary tissues, while metastatic lesions also exhibit considerable cytoplasmic ERβ2 levels. Notably, a higher expression of ERβ1 protein was determined in micropapillary SBOTs compared to LGSOCs. In vitro experiments on LGSOC cell lines (i.e. HOC-7 and VOA-1056) revealed low/absent ERα, PR and AR protein expression, whereas the three ERβ isoforms were all present. Proliferation of HOC-7 and VOA-1056 was not modulated by either the endogenous or the selective synthetic ligands. CONCLUSIONS: These novel findings highlight the need of assessing relative levels of ERα and ERβ isoforms in the total receptor pool in future clinical studies investigating molecular predictors of response to hormonal therapy in LGSOC.
Authors: Jinyou Liu; Gangadhara R Sareddy; Mei Zhou; Suryavathi Viswanadhapalli; Xiaonan Li; Zhao Lai; Rajeshwar R Tekmal; Andrew Brenner; Ratna K Vadlamudi Journal: Cancer Res Date: 2018-04-16 Impact factor: 12.701
Authors: Dane Cheasley; Marta Llaurado Fernandez; Martin Köbel; Hannah Kim; Amy Dawson; Joshua Hoenisch; Madison Bittner; Derek S Chiu; Aline Talhouk; C Blake Gilks; Madawa W Jayawardana; Kathleen I Pishas; Anne-Marie Mes-Masson; Diane Provencher; Abhimanyu Nigam; Neville F Hacker; Kylie L Gorringe; Ian G Campbell; Mark S Carey Journal: NPJ Precis Oncol Date: 2022-06-29
Authors: Yi He; Salvador Alejo; Prabhakar Pitta Venkata; Jessica D Johnson; Ilanna Loeffel; Uday P Pratap; Yi Zou; Zhao Lai; Rajeshwar R Tekmal; Edward R Kost; Gangadhara R Sareddy Journal: Int J Mol Sci Date: 2022-06-28 Impact factor: 6.208